Chronic Heart Failure Therapeutics Pipeline Analysis 2017

Chronic heart failure therapeutic pipeline will increase in near future due to increasing cases of the disease. The prevalence of chronic heart failure is increasing globally due to the factors including obesity, diabetes, high blood pressure, cholesterol, less physical activity and tobacco consumption. These factors are contributing in driving the pipeline analysis for chronic heart failure. According to Centers for Disease Control and Prevention, around 5.7 million adults in the U.S. have heart failure and about half of people die within five years of diagnosis. Asthma is equally prevalent in women than in men.

Explore Report at: https://www.psmarketresearch.com/market-analysis/chronic-heart-failure-therapeutics-pipeline-analysis

Chronic heart failure is a condition, in which heart muscles gets damaged and cannot pump blood properly. This condition slows down the rate of blood flow and increases the pressure, resulting in insufficient supply of oxygen and nutrients to the body. The damage can be a result of heart attack or long-term health issues like diabetes, high blood pressure and heart disease. Heart failure can be caused by several conditions including heart attack, coronary artery disease, thyroid, kidney disease and cardiomyopathy. Some of the symptoms of chronic heart failure include lung congestion, dizziness, fluid and water retention, fatigue, irregular heartbeats and weakness. Chronic heart failure is categorized into two types, systolic dysfunction and diastolic dysfunction. Heart failure is diagnosed by analysing patient’s medical history and examining the symptoms. Also, alcohol consumption, smoking and drugs intake are considered while diagnosing the disease. Certain tests are also conducted for confirmation which includes blood tests, chest X-ray, B-type natriuretic peptide blood test, electrocardiogram, echocardiogram, cardiac catheterization and the ejection fraction test. Chronic heart failure can be treated with strict medications and healthy lifestyle with regular monitoring. The treatment initially aims to decrease the symptoms and improve the quality of life of the patient.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/chronic-heart-failure-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of chronic heart failure therapeutics include Amgen, Inc., Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Daiichi Sankyo Company Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sulfagenix Australia Pty Ltd., Janssen Research & Development, LLC, AstraZeneca plc, Bristol-Myers Squibb Company, MorphoSys AG.

Myelofibrosis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Collaboration and Other Developments

Myelofibrosis is a disease characterized by the build-up of scar tissue in the bone marrow, which leads to genetic mutation in a person’s body. The myelofibrosis therapeutics pipeline is anticipated to increase with the growing need to develop a cure for the problem, and is noticed in approximately one in 500,000 people, in the U.S., usually in the age group of 50 to 80 years, as per the as data provided by U.S. national Library of Medicine. It is a rare form of disease and also happens to patients with thrombocythemia and polycythemia. Moreover, the future developments in therapies are expected to shoot-up.

Explore Report at: https://www.psmarketresearch.com/market-analysis/myelofibrosis-therapeutics-pipeline-analysis

According to National Center for Advancing Translational Sciences, myelofibrosis is disorder of bone marrow, in which bone marrow is replaced by fibrous tissues. In myelofibrosis, bone marrow cannot produce sufficient blood cells and platelets, which leads to weakness, anemia, fatigue and sometimes swelling of spleen and liver. Reduction in number of platelets can cause bleeding and bruising. This condition is also called extramedullary haematopoiesis. The genes of the stem cells such as, JAK2, MPL, CALR, and TET2 genes undergo mutation in somatic stem cells but, the condition is uninherited. Treatments for the problem include chemotherapy, radiation therapy, blood transfusion and surgery.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/myelofibrosis-therapeutics-pipeline-analysis/toc-sample

In November 2013, Baxter International Inc. entered into a licensing agreement with Cell Therapeutics, Inc., to develop and commercialize - pacritinib. Pacritinib is a novel investigational JAK2/FLT3 inhibitor with activity against genetic mutations linked to myelofibrosis, leukemia and certain solid tumors. Pacritinib is currently in Phase II clinical development in patients having chronic malignant bone marrow disorder, myelofibrosis.

Some of the companies having a pipeline of myelofibrosis therapeutics include Incyte Corporation, Novartis AG, Pfizer, Inc., Constellation Pharmaceuticals, Inc., GlaxoSmithKline Plc, Geron Corporation, Baxter International Inc.